INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77501, 'Deflazacort', 'Dabrafenib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.', 'DDInter', 'Concomitant use of deflazacort with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77602/', '', 'Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77502, 'Dabrafenib', 'Prasterone enantate', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77603/', '', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77503, 'Delavirdine', 'Dabrafenib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.', 'DDInter', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).', 'Metabolism', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77604/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More', 'Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77504, 'Deoxycholic acid', 'Dabrafenib', 'Moderate', 'Coadministration with agents that alter hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytics, or agents that commonly cause thrombocytopenia may increase the risk of submental hematoma or bruising in association with deoxycholic acid administration.', 'DDInter', 'Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77605/', '', 'Minoxidil, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, Dupilumab, More', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77505, 'Diazepam', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77606/', '', 'Meprobamate, Lorazepam, Chlordiazepoxide, Halazepam, Hydroxyzine, Oxazepam', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77506, 'Diethylstilbestrol', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77607/', '', 'Histrelin, Leuprolide, Bicalutamide, Triptorelin, Goserelin, Bazedoxifene', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77507, 'Dihydroergotamine', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77608/', '', 'Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77508, 'Disopyramide', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77609/', '', 'Propafenone, Tocainide, Procainamide, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77509, 'Docetaxel', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of docetaxel, which is a substrate of the isoenzyme. Rifampin and hyperforin, a component of St. John''s wort, have been shown to significantly induce the in vitro metabolism of docetaxel in human hepatocyte cultures.', 'DDInter', 'Coadministration of docetaxel with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided unless the benefit outweighs the potential risk of docetaxel underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with docetaxel is unknown.', 'Metabolism', 'Coadministration of docetaxel with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77610/', '', 'Topotecan', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77510, 'Donepezil', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77611/', '', 'Rivastigmine, Galantamine, Tacrine, Memantine, Ginkgo biloba, Aducanumab', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77511, 'Doravirine', 'Dabrafenib', 'Major', 'Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with moderate CYP450 3A4 inducers should generally be avoided. If coadministration is necessary, some authorities recommend that the doravirine dose be increased to 100 mg twice daily (approximately 12 hours apart).', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with moderate CYP450 3A4 inducers should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77612/', '', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Encorafenib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77512, 'Doxorubicin', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.', 'Metabolism', 'Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77613/', '', 'Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin', 'Acalabrutinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, Ripretinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77513, 'Doxorubicin (liposomal)', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.', 'Metabolism', 'Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77614/', '', 'Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin', 'Pralsetinib, Asciminib, Acalabrutinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77514, 'Dronedarone', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77615/', '', 'Propafenone, Tocainide, Procainamide, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Regorafenib, Alpelisib, Trametinib, Erlotinib, Erdafitinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77515, 'Drospirenone', 'Dabrafenib', 'Major', 'RECOMMENDED: Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.', 'DDInter', 'Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib. Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.', 'Metabolism', 'Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77616/', '', 'Estetrol', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77516, 'Duvelisib', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77617/', '', 'Futibatinib, Copanlisib, Alpelisib, Dacomitinib, Lenvatinib, Erdafitinib, Trametinib, Afatinib, Alectinib, Duvelisib, Tivozanib, More', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77517, 'Echinacea', 'Dabrafenib', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', 'DDInter', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77618/', '', 'Entrectinib, Imatinib, Pralsetinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77518, 'Efavirenz', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77619/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More', 'Tivozanib, Futibatinib, Trametinib, Dacomitinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77519, 'Elagolix', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77620/', '', 'Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Pralsetinib, Asciminib, Vandetanib, Neratinib, Nintedanib, Dacomitinib, Tivozanib, Alectinib', 'Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77520, 'Eliglustat', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.', 'DDInter', 'Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', 'Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77621/', '', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77521, 'Elvitegravir', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77622/', '', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77522, 'Encorafenib', 'Dabrafenib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may decrease the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. The extent to which CYP450 3A4 inducers may affect encorafenib exposure has not been studied.', 'DDInter', 'Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77623/', '', 'Axitinib, Futibatinib, Ruxolitinib, Erdafitinib, Neratinib, Selumetinib, Gefitinib, Infigratinib, Capmatinib, Pemigatinib, Dacomitinib, More', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77523, 'Entrectinib', 'Dabrafenib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme.', 'DDInter', 'Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77624/', '', 'Futibatinib, Entrectinib, Regorafenib, Copanlisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77524, 'Enzalutamide', 'Dabrafenib', 'Moderate', 'Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.', 'DDInter', 'Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.', 'Metabolism', 'Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77625/', '', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide', 'Alectinib, Dacomitinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77525, 'Eplerenone', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77626/', '', 'Amiloride, Triamterene, Spironolactone', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77526, 'Erdafitinib', 'Dabrafenib', 'Major', 'Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes.', 'DDInter', 'According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity.', 'Metabolism', 'According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77627/', '', 'Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77527, 'Ergometrine', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77628/', '', 'Misoprostol, Dinoprostone, Oxytocin', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77528, 'Ergotamine', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77629/', '', 'Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77529, 'Erlotinib', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib. If alternative treatment is unavailable and a potent inducer (e.g., carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, St. John''s wort) is to be used for more than a few days, an increase in the dosage of erlotinib should be considered as tolerated at 2-week intervals. Close clinical and laboratory monitoring for altered efficacy and safety, including renal and liver functions and serum electrolytes, is recommended.', 'Metabolism', 'Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77630/', '', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 'Entrectinib, Imatinib, Pralsetinib, Acalabrutinib, Dacomitinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77530, 'Erythromycin', 'Dabrafenib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.', 'DDInter', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).', 'Metabolism', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77631/', '', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Chloramphenicol, Fluorometholone, Azelaic acid, Adapalene, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77531, 'Escitalopram', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77632/', '', 'Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More', 'Dacomitinib, Pexidartinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77532, 'Estazolam', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77633/', '', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Ribociclib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77533, 'Esterified estrogens', 'Dabrafenib', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77634/', '', 'Entrectinib, Pralsetinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77534, 'Estradiol (topical)', 'Dabrafenib', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77635/', '', 'Bazedoxifene, Methyltestosterone, Estetrol, Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77535, 'Estrone', 'Dabrafenib', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77636/', '', 'Bazedoxifene', 'Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77536, 'Estrone sulfate', 'Dabrafenib', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77637/', '', 'Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77537, 'Eszopiclone', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zopiclone, which is a substrate of the isoenzyme.', 'DDInter', 'Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77638/', '', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More', 'Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77538, 'Ethosuximide', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77639/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77539, 'Etonogestrel', 'Dabrafenib', 'Major', 'RECOMMENDED: Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.', 'DDInter', 'Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib. Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.', 'Metabolism', 'Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77640/', '', 'Estetrol', 'Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77540, 'Etoposide', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77641/', '', 'Topotecan', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77541, 'Etravirine', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations of etravirine, which is a substrate of CYP450 2C19, 2C9, and 3A4.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if etravirine is used with CYP450 inducers. Close clinical and laboratory monitoring of antiretroviral response is recommended.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if etravirine is used with CYP450 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77642/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More', 'Futibatinib, Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77542, 'Everolimus', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the blood concentrations and pharmacologic effects of everolimus.', 'DDInter', 'Some manufacturers recommend avoiding concomitant use of everolimus with moderate CYP450 3A4 and/or P-gp inducers such as bosentan, efavirenz, and nevirapine. If concomitant use is required, a dose adjustment of everolimus should be considered to achieve the recommended therapeutic range for the condition being treated. Everolimus whole blood trough levels should be closely monitored during treatment, particularly 2 weeks after a dose increase and 2 weeks after discontinuation of the inducer.', 'Metabolism', 'Some manufacturers recommend avoiding concomitant use of everolimus with moderate CYP450 3A4 and/or P-gp inducers such as bosentan, efavirenz, and nevirapine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77643/', '', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, More', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Brigatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77543, 'Exemestane', 'Dabrafenib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. However, it has also been suggested that suppression of estrogen levels is not affected by the interaction, thus dosage adjustment of exemestane is not required. The extent to which other, less potent CYP450 3A4 inducers may interact with exemestane is unknown. Caution is advised if they are used with exemestane.', 'Metabolism', 'The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77644/', '', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide', 'Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77544, 'Exenatide', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77645/', '', 'Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77545, 'Fedratinib', 'Dabrafenib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fedratinib, which is a substrate of the isoenzyme.', 'DDInter', 'According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77646/', '', 'Futibatinib, Fedratinib, Copanlisib, Alpelisib, Vemurafenib, Erlotinib, Lenvatinib, Erdafitinib, Vandetanib, Trametinib, Afatinib, More', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77546, 'Felodipine', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77647/', '', 'Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Sotalol, Acetylsalicylic acid, Atenolol, Clevidipine, Enalapril, Moexipril, Ramipril, More', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77547, 'Fesoterodine', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.', 'DDInter', 'Caution is advised when fesoterodine is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.', 'Metabolism', 'Caution is advised when fesoterodine is used with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77648/', '', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', 'Pralsetinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77548, 'Flibanserin', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77649/', '', 'Ritodrine, Bremelanotide, Black cohosh, Cabergoline', 'Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Brigatinib, Encorafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77549, 'Fludrocortisone', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77650/', '', 'Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77550, 'Flurbiprofen', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77651/', '', 'Rabeprazole, Phenylbutazone, Tolazoline, Ketoprofen, Tolmetin, Meclofenamic acid, Dimethyl sulfoxide, Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, More', 'Entrectinib, Imatinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77551, 'Fluvastatin', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may alter the pharmacokinetics of HMG-CoA reductase inhibitors. Dabrafenib has been found in vitro to be an inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3. Since many statins including atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid (active metabolite of simvastatin) are thought to be substrates of the hepatic uptake transporters, increased plasma concentrations may be expected during coadministration with dabrafenib, although this has not been studied. On the other hand, dabrafenib has also been reported to be an inducer of CYP450 3A4 and 2C9 in vivo. Reduced plasma concentrations may occur for substrates of these isoenzymes such as atorvastatin, fluvastatin, lovastatin, and simvastatin.', 'DDInter', 'Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors. Clinical and laboratory monitoring are recommended whenever dabrafenib is added to or withdrawn from therapy, and the statin dosage adjusted as necessary. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77652/', '', 'Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More', 'Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77552, 'Glasdegib', 'Dabrafenib', 'Major', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided. If concomitant use cannot be avoided, the glasdegib dose should be increased as tolerated from 100 mg once a day to 200 mg once a day or from 50 mg once a day to 100 mg once a day. Once the moderate CYP450 3A4 inducer has been discontinued for 7 days, the glasdegib dose should return to the dose taken prior to initiating the moderate CYP450 3A4 inducer.', 'Metabolism', 'Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77653/', '', 'Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 'Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77553, 'Glimepiride', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77654/', '', 'Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77554, 'Glipizide', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77655/', '', 'Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin', 'Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77555, 'Glyburide', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77656/', '', 'Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin', 'Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77556, 'Granisetron', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77657/', '', 'Nabilone, Scopolamine, Dronabinol, Rolapitant, Dolasetron, Palonosetron', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77557, 'Guanfacine', 'Dabrafenib', 'Major', 'Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers. For extended-release guanfacine, some manufacturers recommend increasing the dosage up to double the recommended level when initiating therapy in patients who are already receiving a CYP450 3A4 inducer. Further dosage adjustments may be required based on patient tolerance and response. If a CYP450 3A4 inducer is added to existing guanfacine therapy, the guanfacine dosage may be increased up to double the recommended level over 1 to 2 weeks. The dosage should be decreased to the recommended level over 1 to 2 weeks following discontinuation of the CYP450 3A4 inducer.', 'Metabolism', 'Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77658/', '', 'Rauwolfia serpentina root, Reserpine, Methyldopa, Clonidine, Deserpidine', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77558, 'Halofantrine', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77659/', '', 'Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77559, 'Haloperidol', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77660/', '', 'Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More', 'Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77560, 'Halothane', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77661/', '', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77561, 'Idelalisib', 'Dabrafenib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.', 'DDInter', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).', 'Metabolism', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77662/', '', 'Idelalisib, Tivozanib', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77562, 'Iloperidone', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77663/', '', 'Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More', 'Imatinib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77563, 'Imatinib', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of imatinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77664/', '', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 'Sunitinib, Regorafenib, Imatinib, Lenvatinib, Erlotinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Alectinib, Dacomitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77564, 'Imipramine', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77665/', '', 'Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More', 'Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77565, 'Indinavir', 'Dabrafenib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.', 'DDInter', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).', 'Metabolism', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77666/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More', 'Futibatinib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77566, 'Indomethacin', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77667/', '', 'Fluocinolone acetonide, Fluorometholone, Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Phenylbutazone, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, More', 'Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77567, 'Insulin human', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77668/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77568, 'Insulin aspart (aspart)', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77669/', '', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77569, 'Insulin aspart (aspart protamine)', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77670/', '', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77570, 'Insulin degludec', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77671/', '', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 'Lixisenatide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77571, 'Insulin detemir', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77672/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77572, 'Insulin glargine', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77673/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77573, 'Insulin glulisine', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77674/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77574, 'Insulin human (inhalation, rapid acting)', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77675/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77575, 'Insulin human (isophane)', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77676/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77576, 'Insulin lispro', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77677/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77577, 'Insulin lispro (protamine)', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77678/', '', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77578, 'Insulin human (regular)', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77679/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77579, 'Insulin human (zinc)', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77680/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77580, 'Insulin human (zinc extended)', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.', 'DDInter', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77681/', '', 'Lixisenatide', 'Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77581, 'Irbesartan', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77682/', '', 'Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, Eprosartan, Olmesartan, Azilsartan medoxomil, Nebivolol, Telmisartan, Candesartan, Hydrochlorothiazide, More', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77582, 'Irinotecan', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77683/', '', 'Topotecan', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77583, 'Irinotecan (liposomal)', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77684/', '', 'Topotecan', 'Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77584, 'Isavuconazonium', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).', 'DDInter', 'Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.', 'Metabolism', 'Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77685/', '', 'Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77585, 'Isradipine', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77686/', '', 'Clevidipine', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77586, 'Istradefylline', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77687/', '', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77587, 'Itraconazole', 'Dabrafenib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.', 'DDInter', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).', 'Metabolism', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77688/', '', 'Fluconazole, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77588, 'Ivabradine', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivabradine and its active N-desmethylated metabolite, both of which are primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers. The potential for decreased efficacy of ivabradine should be considered.', 'Metabolism', 'Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77689/', '', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More', 'Adenosine, Regadenoson, Alprostadil, Ubidecarenone, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Sotalol, Acetylsalicylic acid, Atenolol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77589, 'Ivacaftor', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77690/', '', 'Nitric Oxide, Doxapram, Elexacaftor', 'Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77590, 'Dabrafenib', 'Ivosidenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77691/', '', 'Tivozanib, Futibatinib, Fedratinib, Regorafenib, Trametinib, Neratinib, Nintedanib, Afatinib, Dacomitinib, Pexidartinib, Alectinib, More', 'Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77591, 'Dabrafenib', 'Ixabepilone', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ixabepilone, which is primarily metabolized by the isoenzyme. Subtherapeutic levels of ixabepilone may result.', 'DDInter', 'The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ixabepilone is unknown. Whenever possible, therapeutic agents with low enzyme induction potential should be considered in patients treated with ixabepilone.', 'Metabolism', 'The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77692/', '', 'Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin', 'Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77592, 'Dabrafenib', 'Ketamine', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77693/', '', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Sevoflurane, Etomidate', 'Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77593, 'Dabrafenib', 'Ketoconazole', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.', 'DDInter', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).', 'Metabolism', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77694/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More', 'Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77594, 'Dabrafenib', 'Lapatinib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided.', 'Metabolism', 'The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77695/', '', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 'Regorafenib, Bosutinib, Lapatinib, Trametinib, Dacomitinib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77595, 'Dabrafenib', 'Larotrectinib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77696/', '', 'Larotrectinib, Lenvatinib, Erdafitinib, Neratinib, Trametinib, Afatinib, Dacomitinib, Alectinib, Binimetinib', 'Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77596, 'Dabrafenib', 'Lefamulin', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', 'Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks. Monitor for reduced efficacy of lefamulin if coadministration is necessary.', 'Metabolism', 'Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77697/', '', 'Futibatinib, Copanlisib, Dacomitinib, Erdafitinib, Abemaciclib, Trametinib, Afatinib, Duvelisib, Tivozanib, Alectinib, Binimetinib', 'Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77597, 'Dabrafenib', 'Lemborexant', 'Moderate', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of lemborexant with potent or moderate CYP450 3A4 inducers should be avoided.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77698/', '', 'Regorafenib, Lenvatinib, Abemaciclib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77598, 'Dabrafenib', 'Lesinurad', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77699/', '', 'Dacomitinib, Pexidartinib, Fedratinib, Bosutinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Regorafenib, Ruxolitinib, More', 'Pegloticase, Febuxostat, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid, Allopurinol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77599, 'Dabrafenib', 'Letermovir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.', 'DDInter', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).', 'Metabolism', 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77700/', '', 'Sunitinib, Futibatinib, Regorafenib, Tucatinib, Vemurafenib, Lenvatinib, Erdafitinib, Trametinib, Vandetanib, Nintedanib, Ibrutinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (77600, 'Dabrafenib', 'Letrozole', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', 'DDInter', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77701/', '', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Vandetanib, Cobimetinib, More', 1767369485);
